ORIC oricpharma.com Net earnings per share growth forecast for next year

Corporate company logo of ORIC Corp (ORIC)

The consensus EPS n+1 forecast chart reinforces the status of ORIC Pharmaceuticals (ORIC) as an innovator in targeted therapy combating molecular tumor resistance. Stable management with deep oncology expertise ensures strict adherence to trial timelines. The value of -11.20 indicates current expectation levels, which are supported by the partnership with Pfizer, the progress of ORIC-114 and ORIC-944, and a significant liquidity position.

ORIC: ORIC Pharmaceuticals Inc Net earnings per one share growth forecast for next year 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for oricpharma.com (ORIC)

- share price and consensus valuation forecast:
Stock Price ORIC Pharma|ORIC - Analyst Consensus Forecast
- market capitalization data:
Market Value ORIC Pharmaceuticals|ORIC - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share ORIC Pharmaceuticals|ORIC - Book Value of Business|Market Capitalization to Book Value Ratio oricpharma.com|ORIC - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio ORIC Pharmaceuticals|ORIC - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital ORIC Pharmaceuticals, Inc.|ORIC - Company Cumulative Debt|Debts to Book Capitalization ORIC Pharmaceuticals|ORIC - Company Long-Term Indebtedness|Company Current Liabilities ORIC Pharmaceuticals|Quick Liquidity Indicator oricpharma.com
- earnings and valuation multiples information:
ORIC - Profit After Payment of Taxes|Projected Future Earnings ORIC Pharmaceuticals|ORIC - Company Value to Net Income|Forward P/E Multiple ORIC Pharmaceuticals|ORIC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ORIC Pharmaceuticals|ORIC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) ORIC Pharmaceuticals|ORIC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months oricpharma.com|ORIC - Earnings per share trend in current year|Expected earnings per share growth for next year ORIC Pharmaceuticals
Fundamental company analysis:ORIC Pharma, ORIC
Brand item of oricpharma.com

Professional capital evaluates ORIC Pharmaceuticals (ORIC) through the lens of targeted therapy commercialization, where expansion rates within the tumor resistance segment determine the future business value. Analyzing the projected EPS growth for the coming year on GURU.Markets, an investor can see the trend of revised earnings expectations; however, a sharp spike in this metric signals rising speculative risks and a decline in the asset's overall stability.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences, Inc.)|Net earnings per one share growth forecast for next year Enliven Therapeutics Inc|Relay Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Expected earnings per share growth for next year|VSTM: Projected earnings per share increase next year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)